Unlocking R&D productivity
Measuring the return from pharmaceutical innovation 2018
Contents

Foreword 03
2018 results for large cap biopharma companies 04
Executive summary 06
Methodology 08
Measuring the return from pharmaceutical innovation 10
Traditional ways of working are no longer sustainable in biopharma R&D 22
Appendix 30
Endnotes 33
Contacts 34

The Deloitte Centre for Health Solutions

The Deloitte Centre for Health Solutions is the research arm of Deloitte LLP’s Life Sciences and Health Care practices. Our goal is to identify emerging trends, challenges, opportunities and examples of good practice, based on primary and secondary research and rigorous analysis.

The UK Centre’s team of researchers, working in partnership with colleagues from the US Center for Health Solutions, seeks to be a trusted source of relevant, timely and reliable insights that encourage collaboration across the health value chain, connecting the public and private sectors, health providers and purchasers, patients and suppliers. Our aim is to bring you unique perspectives to support you in the role you play in driving better health outcomes, sustaining a strong health economy and enhancing the reputation of our industry.

In this publication, references to Deloitte are references to Deloitte LLP, the UK affiliate of Deloitte NWE LLP, a member firm of Deloitte Touche Tohmatsu Limited.

GlobalData

GlobalData is a global data & insights solution provider who, for over 40 years, has been helping over 4,000 companies worldwide to make more timely, fact-based decisions. Our mission is to help our clients succeed and be more innovative by decoding the future and reducing the noise & uncertainties surrounding the world of today. We do this by providing market data, competitive insights and end-user perspectives which are delivered to our clients in an integrated way through a variety of different tools.
Foreword

Welcome to *Unlocking R&D productivity*, the ninth annual report from the Deloitte Centre for Health Solutions exploring the performance of the biopharmaceutical industry and its ability to generate returns from investment in innovative new products.

Since we began our series in 2010, we have seen a steady march of average R&D costs increasing and average forecast sales decreasing nearly every year from our company cohorts, resulting in declining predicted returns from R&D investment. In light of this, we are also seeing strategic shifts occurring across the industry, with many companies testing new approaches to R&D costs alongside new treatments to drive improved productivity. The reign of data is beginning, as analytics on large data sets – often by artificial intelligence and machine learning algorithms – can find hidden patterns and decipher new links between disease and the human body's response.

The resulting data insights are driving innovation in gene therapies and stem cell-based therapies that were only theoretical in years past. However, it is our view that the industry has yet to unlock the full potential of truly breakthrough R&D capabilities, which will require a complete digital transformation to maximise R&D productivity and simultaneously deliver the next generation of scientific breakthroughs. We recognise that moving away from tried and trusted methods, enshrined by regulators, toward new ways of operating for entire organisations will take time, but we believe the current levels of returns should be a catalyst for these shifts.

Our *Measuring the return from pharmaceutical innovation* series tracks the return on investment that 12 large cap biopharma companies might expect to achieve from their late-stage pipelines. Our analysis is focused on assets that are currently in late-stage development and expected to launch within the next four years, using data from publicly-available, audited annual reports and forecasts provided by GlobalData.

For the fourth consecutive year, our analysis also tracks the performance of an extension cohort of four smaller, more specialised biopharma companies, which allows us to compare and contrast their performance against the original cohort. This helps deepen our insight into company and portfolio characteristics that produce higher R&D returns.

In our 2017 report, we focused on emerging technologies that have the potential to optimise the research-based biopharma value chain. In this, our 2018 report, we have supplemented our core quantitative analysis with a view of how the nature of work, who does it, and where it gets done, is changing as a result of an increasingly challenging R&D environment. The reports over two years combine to offer a holistic view of how change at scale could occur to improve returns.

We hope you find this report engaging and thought-provoking, and we look forward to your feedback on the findings and their implications for biopharma in the coming year to help continue to evolve our thinking!

Colin Terry  
Partner  
EMEA Life Sciences R&D Advisory  
Deloitte LLP  
colterry@deloitte.co.uk

Neil Lesser  
Principal  
US Life Sciences R&D Strategy  
Deloitte Consulting LLP  
nlesser@deloitte.com
2018 results for large cap biopharma companies

R&D returns have fallen to the lowest level in nine years:
- 2018: 1.9%
- 2017: 3.7%
- 2016: 4.2%
- 2015: 4.2%
- 2014: 5.5%
- 2013: 4.8%
- 2012: 7.3%
- 2011: 7.6%
- 2010: 10.1%

Late-stage pipelines are increasingly comprised of oncology assets:
- 2010: 18%
- 2018: 39%

The cost to bring an asset to market has increased to record levels in 2018:
- 2010: $816m
- 2018: $407m

Forecast peak sales per asset have more than halved since 2010:
- 2010: $1,188m
- 2018: $2,168m
R&D returns have fallen to the lowest level in nine years:

- 2018: 1.9%
- 2017: 3.7%
- 2016: 4.2%
- 2015: 4.2%
- 2014: 5.5%
- 2013: 4.8%
- 2012: 7.3%
- 2011: 7.6%
- 2010: 10.1%

Late-stage pipelines are increasingly comprised of oncology assets.

The cost to bring an asset to market has increased to record levels in 2018.

Forecast peak sales per asset have more than halved since 2010:

- 2010: $1,188m
- 2018: $407m

2018 results for smaller, more specialised biopharma companies:

More specialised biopharma companies are outperforming large cap biopharma, despite the higher development cost, due to higher projected pipeline values:

- Returns: 9.3%
- Forecast sales: $1,165m
- Development costs: $2,805m

Unlocking R&D productivity by embracing the future of work:

- Build machine learning algorithms to inform decision-making
- Automate repetitive tasks to take on higher value-add work
- Invest in innovation hubs to gain access to talent and ideas
- Establish open and collaborative partnership models with innovators, entrepreneurs, and technology companies
- Develop digital and analytical skills at all levels
- Consider non-traditional sources of talent such as crowdsourcing or gig workers
Advances in science and technology are transforming the world around us. However, the biopharmaceutical (biopharma) industry has yet to unlock the value of many of these advances, despite the potential to increase R&D productivity radically.

Biopharma’s efforts to produce life-saving or life-changing drugs involve an incredibly complex and capital-heavy R&D environment, guided by intense regulatory scrutiny that aims to ensure the safety and efficacy of these drugs. Upon approval, the industry seeks to recoup the value of its investment in innovation, but recouping these investments is becoming increasingly difficult. The industry is under mounting pressure to demonstrate the value of its products, as new drugs are more expensive to develop and target smaller patient populations.

Our series Measuring the return from pharmaceutical innovation has provided insight into the state of R&D in biopharma since 2010. Our estimates of the return on investment that 12 large cap biopharma companies might expect to achieve from their late-stage pipelines have shown that, despite launches of many successful products, the long-term outlook for the industry continues to be increasingly challenging. For the fourth consecutive year, our analysis includes an extension cohort of four smaller, more specialised companies. For both cohorts, we calculate the internal rate of return (IRR) and use it as a proxy to measure biopharma’s ability to balance R&D investment (initial and ongoing capital outlay) with the cash inflows (drug sales) the industry is projected to receive as a result of this investment. These returns serve as a basis for discussion and debate among the many stakeholders across biopharma to help determine the value of investing in innovation.

Our analysis explores strategies to maximise returns, either by reducing the costs of R&D or by increasing the value of late-stage pipeline assets. This year, we also look at the skills and talent needed to work in a technology-enabled R&D environment.

Projected returns decline to their lowest levels for both cohorts
Our original cohort of 12 large cap biopharma companies have seen their projected returns drop to 1.9 per cent, the lowest result in our series, down 1.8 percentage points from 2017 and 8.2 percentage points overall from 2010. This corresponds to an average decline of just over one percentage point per year for our original cohort. Returns for our extension cohort also declined to their lowest levels, from 12.5 per cent in 2017 to 9.3 per cent in 2018. This was driven by a strong year of commercialisation, with the four companies in our extension cohort transferring pipeline value into commercial success.

Declining returns are the result of internal and external productivity challenges
R&D productivity is a factor of the cost to develop an asset and the expected sales from approved assets. The average cost to develop an asset, including the cost of failure, has increased in six out of eight years. In 2018, our original cohort’s average cost to develop an asset has increased to $2,168 million – almost double the average cost in 2010 of $1,188 million. Similarly, our extension cohort’s average cost has increased to $2,805 million – up from $1,034 million in 2013, the first year of our extension cohort analysis.

Conversely, forecast peak sales per asset for our original cohort have moved in the opposite direction. After a slight uptick last year, forecast average peak sales declined slightly to $407 million, less than half the value in 2010 ($816 million). This decline does appear to have stabilised to some extent though. For our extension cohort, the trend is different, with forecast peak sales per asset increasing from $952 million in 2013 to $1,165 million in 2018.

While the original cohort are continuing to contribute to significant patient value through product approvals, the value lost through the successful transition of developmental assets into the commercial portfolio is not being replenished by new assets from earlier stages of development or licensing deals. Overall, the number of late-stage pipeline assets in the original cohort’s pipeline has decreased 23 per cent since the beginning of our series, from 206 assets in 2010 to 159 assets in 2018.

Since 2014, there has been an increase in the number of assets receiving special status (Fast Track, Breakthrough, Orphan, Priority Review), and while this and the implementation of new technology is undoubtedly having an impact on late-stage development cycle times, our data suggests that on average, clinical cycle times have continued to increase.
A transformational change in R&D productivity is required to reverse declining trends in R&D returns across the biopharma industry.

The successful digital transformation of biopharma R&D will also require companies to overcome leadership, funding and cultural challenges. Digitally literate R&D leaders need to find talent with analytical skill sets and should look beyond the traditional sources of talent to help initiate, implement and sustain digital transformation efforts. Furthermore, maintaining talent will require utilising the next generation of technology and providing opportunities for constant learning and growth. Biopharma companies will compete for talent with numerous other industries and will need to provide competitive compensation packages, opportunities for growth and a tech-savvy work environment – combined with a compelling patient-centric mission statement – to help attract talent. The current R&D model, which historically has recruited and promoted talent based on a legacy set of skills and knowledge, needs to accommodate these new skills quickly.

We believe the time for biopharma companies to start transforming their R&D is now. Digital transformation is a continuous, fast-moving and multi-year process that even fast followers may struggle to keep up with. Companies should start adopting new approaches to work and hiring new types of talent now. Those that wait will struggle to compete with those that are already adopting new ways of working and hiring the talent that is needed and in short supply across the world.
Methodology

Our series *Measuring the return from pharmaceutical innovation* focuses on the projected returns from the late-stage pipelines of an original cohort of 12 large cap biopharma companies. Our four most recent reports also include an extension cohort of four smaller, more specialised companies. We use these two cohorts as a proxy to measure the industry’s ability to balance initial capital outlay with cash inflows biopharma companies are projected to receive as a result of this investment.

**Methodology overview: A consistent approach to objective benchmarking**

Our consistent and objective methodology throughout the lifetime of our series allows us to measure industry performance across the original and extension cohorts. We use two inputs to calculate the Internal Rate of Return (IRR) from a company’s late-stage pipeline: the total spend incurred bringing assets to launch (based on publicly available information from audited annual reports or readily available from third-party data providers) and an estimate of the future revenue generated from the launch of these assets. The infographic on the proceeding page illustrates our methodology, showing both the static and dynamic measures of R&D returns.

**Our analysis accounts for multiple factors:**
- forecast revenue splits where a particular compound is in development for multiple indications
- the impact of in-licensing and M&A on R&D costs
- success rates in late-stage development
- the impact of clinical cycle times

Given the inherent risks in undertaking R&D and the need to generate a complete view of R&D returns, our analysis also accounts for the cost of failure. Therefore, our calculations of the total spend incurred in developing and launching assets include the expenditure on terminated programmes and compounds. However, we limit our analysis to assets currently in late-stage development (Phase II breakthrough, Phase III and filed), which reduces our forecast risk to an acceptable level, as late-stage development contains a lower level of volatility than earlier phases of development.

We calculate the static year-on-year rate of return and also include the three-year average figure, first introduced in our 2015 report. This reduces the volatility associated with the static measures and provides a more well-rounded view of an organisation’s projected R&D returns to match the long time periods over which decisions within R&D become impactful (see Figure 16 in Appendix).

For the fourth year, we have also analysed the R&D returns of four smaller, more specialised biopharma companies (covering the period 2013-18). The inclusion of this extension cohort provides a greater understanding of their long-term performance and insight into factors linked to improved R&D productivity.*
Previously published data for 2016 and 2017 have been restated in this report as a result of minor corrections. While this creates minor changes in the company and consolidated figures, the trends remain consistent with the data published originally.

Source: Deloitte LLP, 2018
Measuring the return from pharmaceutical innovation

The original cohort’s projected returns drop below 2 per cent
For the second year running, the consolidated returns for the 12 original cohort companies have declined, with projected 2018 returns of 1.9 per cent – a decrease of almost two percentage points from 2017, and a decrease of 8.2 percentage points overall from 2010 (see Figure 1). This represents an average decline of just over one percentage point per year.

While there remains some variation within the returns of the original cohort of companies, the range in values between the top and bottom performer is the narrowest it has ever been, at 10.4 per cent (see Figure 1). With the overall decrease in both absolute returns and the range, just three of the 12 companies managed to improve their projected returns in 2018, and only two companies achieved returns above five per cent.

Figure 2 shows the aggregate drivers of change for the original cohort between 2010 and 2018, referencing this to the year-on-year return on late-stage portfolio. It then illustrates the key drivers of change between 2017 and 2018.

As assets are approved, forecast revenues move from the late-stage pipeline into the commercial portfolio. While this ultimately increases the value of these assets from a patient perspective as the products become available within the health care system, they move out of the scope of our analysis and decrease the value of the late-stage portfolio. During the 2018 report year between 1 May 2017 and 30 April 2018, the original cohort had a total of 49 asset launch events, with forecast total sales of $229 billion. This resulted in a 2.7 percentage point decline in projected returns, the fourth highest decrease due to approvals since our analysis began in 2010.

Set against the successful approvals, late-stage R&D continues to be inherently risky, and this continues to be underlined by the decrease in returns due to late-stage failures.

Figure 2 shows the aggregate drivers of change for the original cohort between 2010 and 2018, referencing this to the year-on-year return on late-stage portfolio. It then illustrates the key drivers of change between 2017 and 2018.

As assets are approved, forecast revenues move from the late-stage pipeline into the commercial portfolio. While this ultimately increases the value of these assets from a patient perspective as the products become available within the health care system, they move out of the scope of our analysis and decrease the value of the late-stage portfolio. During the 2018 report year between 1 May 2017 and 30 April 2018, the original cohort had a total of 49 asset launch events, with forecast total sales of $229 billion. This resulted in a 2.7 percentage point decline in projected returns, the fourth highest decrease due to approvals since our analysis began in 2010.

Set against the successful approvals, late-stage R&D continues to be inherently risky, and this continues to be underlined by the decrease in returns due to late-stage failures.
A consistent trend highlighted throughout our series of reports has been that, while companies continue to innovate, they have been unable to replenish late-stage pipelines at a rate that compensates for the successful approval and flow of value into the commercial portfolio and loss through late-stage attrition. This year has seen an increase of 1.6 percentage points, driven by 50 assets with forecast lifetime sales of $171 billion – an improvement on our 2017 analysis, where we highlighted that the increase of 1.0 percentage points in projected returns due to new assets entering pipelines was the lowest ever recorded. However, our 2018 calculation is still below average and is the third lowest refresh of value in late-stage pipelines we have recorded.

On a more positive note, for only the third time in our series, the original cohort has been successful in de-risking and increasing returns from existing late-stage pipeline assets, with a 0.7 percentage point increase in 2018. This increase in forecast revenues from existing assets has been largely driven by positive clinical trial data, class effect and delays to loss of exclusivity in forecasting assumptions.

**Figure 1. Return on late-stage portfolio, 2010-18 – original cohort**

Source: Deloitte LLP, 2018
Figure 2. Drivers of change in IRR 2010-18 consolidated, 2010-18 year on year and 2017-18 – original cohort

Source: Deloitte LLP, 2018
Declining returns are the result of internal and external productivity challenges

This year has seen a further decline in the number of assets in the late-stage pipelines to a new low of 159 (see Figure 1). This is a decrease of 10 per cent from 2017 and a 16 per cent decrease from the average of the previous eight years. Consequently, the reduction in the number of assets in late-stage development has contributed to a 0.7 percentage point decrease in returns between 2017 and 2018 (see Figure 3).

Figure 3. Overall impact of pipeline factors on change in IRR, 2010-17 and 2017-18 – original cohort

Source: Deloitte LLP, 2018
The average cost to develop an asset continues its upward trend

R&D spend by the original cohort continues to increase, with companies in the original cohort spending $78 billion in 2018, corresponding to an increase of 15 per cent in underlying R&D expenditure since 2010. It is not surprising then that core R&D costs have led to a decline in projected returns of 0.9 percentage points (see Figure 2) and that for the second year running, the average cost to develop an asset from discovery to launch has increased for the original cohort. The average cost in 2018 is $2,168 million, an increase of $362 million from 2017 (see Figure 4). As in 2017, this is largely due to the smaller number of assets currently in late-stage pipelines (159), which is the denominator in the calculation and is known to be relatively volatile.

At constant late-stage asset numbers (177 from 2017), the average cost per asset would have remained below the $2 billion mark, at $1,948 million, an increase of $142 million. On a three-year rolling average basis, the average R&D cost is now tracking at $1,793 million for 2016-18 (see Figure 17 in Appendix).

However, it should be noted that there is significant variance in cost per asset within the original cohort companies, with the range between the highest and lowest performer in 2018 the second highest over the nine-year period.

Figure 4. Average R&D cost to develop a compound from discovery to launch, 2010-18 – original and extension cohort

R&D spend by the original cohort continues to increase, with companies in the original cohort now spending $78 billion in 2018, corresponding to an increase of 15 per cent in underlying R&D expenditure since 2010.
Forecast peak sales per asset have seen a slight decline in 2018 but remain relatively stable
While there has been a significant decrease in returns due to the decline in the number of late-stage assets over the past few years, the decrease in the average forecast peak sales per asset has, and continues to be, the greatest reason for decline in R&D returns of the pipeline factors highlighted in Figure 3.

This year has seen a decline in average forecast peak sales per pipeline asset to $407 million relative to the year-on-year increase observed between 2016 and 2017 (see Figure 5). However, the fall appears to have levelled off, particularly when considering that 2018 has the lowest observed range in average forecast peak sales for the original cohort.

This year has seen a decline in average forecast peak sales per pipeline asset to $407 million relative to the year-on-year increase observed between 2016 and 2017.
Taken as a measure of pipeline quality alongside the average peak sales per asset, the contribution of blockbuster products to overall forecast revenue has stabilised to some extent, with assets in this category averaging 44 ± 7 per cent over the past six years (see Figure 6). However, the tier of assets below this appears to be declining, and smaller value assets (those forecast to generate peak revenues no greater than $500 million) are now contributing 33 per cent of total forecast revenues. This is the largest amount we have seen during our analysis and suggests that returns are being propped up by a relatively small number of blockbuster assets, with an increasingly long tail of smaller assets.

As we have highlighted previously, blockbuster costs without corresponding blockbuster sales or volume of assets is not an equation that will drive sustainable returns from the investment in innovation. With average forecast peak sales of just over $400 million, the operating model needs to be able to do this for at least a third of the current cost per asset, as highlighted in our 2016 report.1

Source: Deloitte LLP, 2018
The extension cohort has seen a strong year of asset commercialisation

The extension cohort, like the original cohort, has also seen a decline in projected returns. The four extension cohort companies, however, are still outperforming their larger peers within the original cohort with an IRR of 9.3 per cent – only once bettered by the original cohort, in 2010 (see Figure 7).

Our 2017 analysis identified pipeline replenishment as the largest driver of change in IRR for the extension cohort, with the entry of nine new assets into late-stage pipelines. However, 2018 has been a year of commercialisation, with the launch of five assets, resulting in a flow of 2.9 per cent in projected returns out of the late-stage pipeline and into the health care system (see figure 8). In contrast to 2017, just nine assets have entered late-stage development – one less than last year but contributing to an increase in returns of just 1.2 per cent compared to the 5.1 per cent increase in 2017.

However, 2018 has seen an improvement in returns due to existing assets that have remained in the pipeline year on year (0.8 per cent). The primary driver of this increase was positive trial data, and to a lesser extent, class effect and competitor failure. The 0.3 per cent decline in returns due to terminations, representing three assets (four terminations in 2017), is the second lowest decrease due to terminations recorded (see Figure 8).

2018 has seen an improvement in returns due to existing assets that have remained in the pipeline year on year (0.8 per cent). The primary driver of this increase was positive trial data, and to a lesser extent, class effect and competitor failure.
A decline of 2.0 per cent, due to pure R&D costs, has also been a significant contributor to this year’s decrease in projected returns. This has been driven by an increase in underlying raw R&D expenditure of $13 billion since 2017 – an increase of 16 per cent, and $52 billion since our first measurement in 2013. This corresponds to an increase of 125 per cent at a compound annual growth rate of 17 per cent since 2013. This is in line with revenue growth of $40 billion and 104 per cent since 2013, which is now being invested in scaling up R&D efforts. That this correlates with a decline in returns does pose the question of how sustainable the increase in underlying R&D spend will be.

Average forecast peak sales for the extension cohort have remained at blockbuster levels in 2018 at $1,165 million, slightly down on last year’s $1,221 million (see Figure 5). This is now the fourth year out of six that the extension cohort has achieved average forecast peak sales of blockbuster status ($1 billion) or more, which is in stark contrast to the average forecast peak sales of $407 billion achieved by the original cohort. Reasons for this difference are likely to include greater agility to take risks on truly innovative assets and a less diversified portfolio aimed at replacing cash flows lost as a result of patent cliffs that continue to impact the original cohort.

In our 2017 analysis, the extension cohort saw an increase in its average cost to bring an asset to market rise above $2 billion for the first time, reaching $2,111 million. In 2018, this cost has increased significantly and now stands at $2,805 million, an increase of 33 per cent. The primary reasons for this rise for the extension cohort are a sizeable increase in core R&D expenditure attributable to the late-stage portfolio, in-process research and development (IPR&D) incurred as the result of business combinations and a decrease in the number of assets (23 in 2018, compared to 24 in 2017).
Original cohort therapy area focus continues to shift towards oncology
The move by the original cohort towards oncology has been a consistent trend over the past six or so years, with oncology assets now representing 39 per cent of the original cohort’s late-stage pipelines, compared to 18 per cent in 2010 (see Figure 9). Interestingly, while there has been a marked percentage increase, this represents a decrease of $49 billion in total forecast revenues, suggesting the shift towards oncology has been driven by the decrease in revenues from other therapy areas and the pull factors associated with the move to immuno-oncology drugs.

Clinical cycle times continue to lengthen despite individual success stories
Since 2016 there has been a sizeable increase in the percentage of late-stage assets that have either a Fast Track, Breakthrough, Orphan or Priority Review designation. In 2017 and 2018, this stood at just over a third of the pipeline by number of assets (see Figure 10).
The aim of these designations, awarded by the FDA, is to give pharmaceutical companies incentives for developing drugs for conditions with limited or no treatment options, or for developing drugs offering significant advantages over existing treatments. One of the incentives is usually a quicker drug development timeline.

However, our data shows that companies are now taking longer than ever to bring drugs that do not have special designations through clinical testing (see Figure 11). While this result is unexpected considering the increase in assets with special designation status, the original cohort’s continued move towards developing complex assets within therapeutic areas such as central nervous system (CNS) and oncology may be a contributing factor (see Figure 9). In the case of oncology, the complexity associated with developing cancer therapies mean development timelines tend to be longer (see Figure 12), which is partly driven by an insufficient number of patients eligible to register in clinical trials. There are over 1,000 clinical trials underway using immunotherapies alone, and not enough patients to complete every trial within the desired timeframe.2

While Figure 11 indicates that clinical cycle times have increased, Figure 12 illustrates that oncology cycle times may finally be starting to shorten, particularly with a number of immuno-oncology trials being stopped early due to impressive efficacy profiles. The recent approval of Sanofi and Regeneron’s Libtayo (cemiplimab) is one example of this.3 As with the complexity of the trials themselves, the underlying factors are complex, and it will be interesting to see if this trend continues (see Table 1).

The complexity associated with developing cancer therapies mean development timelines tend to be longer, which is partly driven by an insufficient number of patients eligible to register in clinical trials.
Table 1. Factors influencing the change in oncology clinical cycle times

<table>
<thead>
<tr>
<th>Factor</th>
<th>Potential to shorten cycle times</th>
<th>Potential to lengthen cycle times</th>
</tr>
</thead>
<tbody>
<tr>
<td>Build expertise</td>
<td>Improvement of oncology trial efficiency as a result of built expertise</td>
<td>Efforts to use earlier survival end points when acceptable by regulatory authorities (e.g., overall survival at 6 months/1 year as opposed to 2+ years historically)</td>
</tr>
<tr>
<td>Earlier end points</td>
<td>Efforts to use earlier survival end points when acceptable by regulatory authorities (e.g., overall survival at 6 months/1 year as opposed to 2+ years historically)</td>
<td>Slower therapeutic action</td>
</tr>
<tr>
<td>Shift towards immuno-oncology</td>
<td>Immuno-oncology studies shortening trial duration to accelerate filing (e.g., Libtayo)</td>
<td>Immuno-oncology drugs are associated with increased efficacy and tolerability (physician-driven acceleration of patient enrolment, increased patient compliance)</td>
</tr>
<tr>
<td>Shift towards personalised medicine</td>
<td>Increased efficacy and tolerability due to biomarker-based stratification approach</td>
<td>Potentially longer initiative/enrolment phase</td>
</tr>
<tr>
<td>Shift towards combination therapies</td>
<td>Increased patient rollover and efficacy</td>
<td></td>
</tr>
</tbody>
</table>

Source: GlobalData and Deloitte LLP, 2018

Figure 12 illustrates that other therapy areas are showing a different trend, with infectious disease (ID) demonstrating the impact of a shift away from indications with relatively short treatment regimens and well-defined endpoints such as Hepatitis C. Instead, ID is shifting towards indications such as HIV, which require a longer treatment and trial duration. Both cardiovascular (CV) and metabolic therapy (Met) areas have also seen a recent increase after several years of stability. For CV, pipelines have shifted towards the prevention of heart failure, especially associated with chronic kidney disease, which often result in longer clinical trials. Met have seen an increase in trial duration for diabetes studies, which represents a large segment of this therapy area, due to longer end-points needed to demonstrate efficacy benefits over the current standard of care.

Cycle time is a key driver of R&D productivity, and as such, the ability to embed new ways of working within an organisation will be a key factor in ensuring that accelerated filings and other cycle time success stories become the norm rather than isolated successes. We will explore this further in the following section.
Traditional ways of working are no longer sustainable in biopharma R&D

The continually increasing cost of R&D reflects increasing portfolio complexity, the shift towards personalised medicine and the need to generate evidence to support diverse global regulatory and reimbursement requirements. Adapting to these new market demands using traditional approaches and ways of working is not sufficient to reverse the declining trend in IRR, pointing to the need for a transformational change in the way R&D is conducted.

Biopharma R&D leaders should consider how the nature of work, who does it, and where it gets done needs to change. For example, the process to deliver the ‘clinical supply’ for CAR-T therapies is fundamentally different from that of traditional small molecules or biologics. Consequently, roles and responsibilities needed within the organisations and supply chain differ significantly. Adapting these roles will require an understanding of the overall care delivery process, which involves a procedure and individualised development of the therapy, as opposed to mass manufacturing.

A transformational change in how R&D is executed will also require significant technology investment. By using technology to automate repetitive and administrative tasks, companies shift their employees’ focus towards higher-value activities. Furthermore, significant aspects of work can be done by employees beyond those who are on the company’s payroll. For example, crowdsourcing or gig workers are able to provide new insights or supplement the workforce. Work can also shift outside of the four walls of a biopharma company, resulting in an expansion of the nature of partnerships or collaborations and a re-evaluation of the company footprint. These changes require an operating model that enables non-traditional collaborations, data-driven decision-making and faster cycles of innovation.

Technology is catalysing exponential improvement in R&D productivity

Across industries, technology is now replacing or augmenting work that used to be done by humans. Machines automate repetitive tasks so they are done faster, cheaper and more accurately. This is equally true in clinical development, where many tasks are administrative in nature. At the same time, the industry is witnessing a proliferation of R&D and health care data sources, driven by the digitisation of health records and the exponential growth of patient-centred health care technologies (such as apps and sensors) that generate large volumes of data. Machines help to analyse these data and enable more informed decision-making, clinical trial design and identification of new drug candidates or indications.

Automation

Augmenting human productivity with AI technologies such as robotic process automation (RPA), natural language processing (NLP) and natural language generation (NLG) can improve the speed, accuracy and quality of tasks, leading to a more productive and cost-effective workforce. Thirty per cent of repetitive, standardised tasks that do not require judgement, such as quality or edit checks, can be automated (see Figure 13).4 Personnel working on these tasks are able to free up their time to work on more value-added activities (see sidebar on following page).

NLP can also be used to unlock insight from real-world data, particularly from electronic health records (EHRs), and transform data into evidence. Ninety-five per cent of companies surveyed in our 2018 study on the status of biopharma real-world evidence capabilities reported that they plan to use machine learning to support real-world data analyses in the coming years.5

A transformational change in how R&D is executed will also require significant technology investment.
The medical writer of the future

The current medical writer is responsible for writing and coordinating document development for regulatory dossiers, including managing timelines and reviews to ensure that the published document undergoes the appropriate quality control checks. A high proportion of their time is spent on manual activities, including writing repetitive, descriptive text within a well-defined language set.

In the future, AI, component-based authoring and machine learning will streamline the writing process, automatically populating and utilizing boilerplate text so that medical writers write essential content only once, improving the quality of submissions and speeding up the internal review process. Increased capacity allows:

- a greater focus on value add elements of a dossier such as the interpretation of results, to improve the relevance of submissions, improve analysis and enable a faster, more efficient regulatory process
- writers to take on new activities across the value chain such as working with clinical scientists to interpret results or supporting the production of literature for journals.
Algorithms to support decision-making

R&D decision-making and clinical trial design could be improved by cognitive technologies. For example, applying machine learning to EHRs can enable the design of more realistic inclusion/exclusion criteria, and the creation of a more robust investigator network. These technologies can also drive the shift towards personalised medicine by differentiating products at a subpopulation level, allowing a better understanding of who will benefit from specific treatments. Populations of patients unlikely to benefit from a particular treatment can be filtered out in favour of those who will benefit the most, maximising the value of the treatment and minimising adverse effects or ineffective treatments. Cognitive technologies can also improve predictive analytics and accelerate the capabilities of safety and regulatory functions.

Cognitive technologies can also significantly transform the search for new drugs, either through drug discovery or business development. Currently, discovery is often done in scientific silos and in fragmented experiments. In the future, cognitive technologies will integrate and analyse this data from experiments to identify new targets or promising drug candidates. Some companies are investing heavily in AI to support drug discovery. Further, the search for external innovation will shift from being one that is based on scouting, building relationships and interpreting limited data to one that is based on algorithms that can scan the landscape and analyse data to identify the best opportunities to pursue. This will significantly expedite the timeline for discovering or developing promising new drug candidates from a wider base of research than a single scientist or company.

Implications for the future of work in R&D

New skills, new sources of talent and a scaled approach to implementation are required for companies to realise the benefits of automation and cognitive technologies.

Shifting skill sets

The development of internal capabilities able to embed new technology, platforms and predictive algorithms requires new technical and analytical skills. Utilising big data will require not only data science skills to clean and analyse the data, but also the ability to frame the right questions, identify the right hypotheses and interpret the results of data analyses. This will change the nature of work for future clinical researchers. For example, rather than focusing on capturing, cleaning and structuring the data, they will be focused on interpreting the data.

The next generation of R&D talent needs to be agile, digitally literate and open to continuous learning, as technology and capabilities continue to evolve rapidly. Employees need to have the right balance of skills not only to understand how to apply the technology, but also to interpret the strategic and clinical significance of data analysis. Some companies will look to other industries to seek out this talent (see sidebar).

Biopharma companies have to consider upskilling current clinical and regulatory employees to obtain basic levels of digital literacy and partnering them with those who have a deeper understanding of technology. For example, companies may have to consider creating a new role that interfaces between data science, clinical development and regulatory teams. That person could be responsible for translating business questions into data projects, and also ensuring compliance within existing regulatory frameworks. Further, siloes between functions are likely to break down in the future. Companies should rotate people among R&D, regulatory and commercial functions to build a more adaptable and flexible workforce.

Looking for talent in non-traditional places

When a senior team member quit, the Head of Regulatory at a biopharma company saw an opportunity to bring in a fresh perspective and initiate a major cultural change. Instead of the traditional approach of hiring someone with 20 years of regulatory experience from another biopharma company, he decided to hire someone from a technology company with no life sciences regulatory experience. This person could help transform how the regulatory team utilises technology internally and partners with existing regulatory experts.
**New sources of insight**
Companies could gain more insight from patients by treating them as collaborators or co-creators instead of subjects in the research process. This can be achieved through patient representation on advisory boards, study pilots, surveys, focus groups and crowdsourcing input. Some companies have already started to crowdsource patient and researcher input on clinical trial design. For example, one biopharma company is working with a digital drug development services company to crowdsource input for the design of a trial for the rare disease sarcoidosis. They are seeking input on overall trial design, adaptive design and comparator treatments.6

**Deciding where to start**
With so much potential for productivity improvement, determining where to start automating processes can be daunting. R&D leaders should identify potential use cases where automation can be applied and quantify the business value for each, and also assess the operational implications. Companies should prioritise the opportunities that free up the most capacity with the lowest cost to implement and the ability to reduce risk and improve the quality of deliverables. Additionally, tasks that are expected to scale significantly and require increasing capacity in the future have to be considered as high-priority for automation. Some innovative companies have crowdsourced ideas from employees on what parts of their jobs they feel could benefit from automation. Ideas are judged, and winning teams are provided the funding needed to buy or build a bot to automate those tasks. Employees working in jobs that will become partially automated could shift their focus to adjacent activities that add greater value to the task at hand, which will require new skills or additional training. Making automation technology and skills readily available via a centre of excellence or central team ensures opportunities can be realised in a timely and consistent manner.

Most companies are starting with automation of rule-based and repetitive processes before exploring opportunities to apply machine learning. Implementing machine learning requires advanced cognitive skills and large amounts of data that can be used to train machines. Further, researchers need to be comfortable with understanding and explaining the ‘black box’ of machine learning algorithms, especially if the output is used for regulatory submissions. Biopharma companies need to compete with other industries to seek out technical talent that can establish machine learning algorithms and pair them with existing clinical and regulatory experts who can help guide the design.

Companies need to look externally to develop cognitive capabilities or access data to feed AI algorithms. Some companies have already partnered with AI companies to help speed up drug discovery. Others are partnering with AI companies to help identify investigators and patients who could be recruited into clinical trials. Importantly, many companies are sourcing real-world evidence through unique partnerships with technology companies or hospital systems.

With so much potential for productivity improvement, determining where to start automating processes can be daunting. R&D leaders should identify potential use cases where automation can be applied and quantify the business value for each, and also assess the operational implications.

**Deloitte’s view:**
It is imperative that biopharma companies fully embrace the wealth of opportunities for productivity improvement linking workflow, cognitive and analytics to data ‘oceans’ being created in R&D. These include optimising the use of automation in a regulated industry, building capability to extract the most meaning from the wealth of available data, evaluating and developing the capabilities and skills of their existing workforce and sourcing critical external skills. Taking these actions will ensure they have sufficient capacity to develop and apply machine learning algorithms and interpret results in a clinical and regulatory context.
Partnerships and collaborative R&D models will result in new governance and operating models
Companies have long realised the importance of partnerships with patient advocacy groups, academia and technology companies to strengthen relationships with patients, researchers and innovators. For biopharma companies, partnerships help broaden patient access, build reputation and expand research networks and capabilities.

Accessing patient data
The value of cognitive analyses depends on the strength of the data set that the machine is analysing, and companies need to pursue partnerships to access proliferating sources of patient health care data. These partnerships will result in non-traditional ways of working with traditional stakeholders such as health plans, providers, advocacy groups, or net new relationships with consumer technology companies. The Deloitte 2018 Health Care Consumer Survey shows that consumers tend to trust academic medical centres, patient advocacy, specialty and medical societies over biopharma companies, and they are more willing to share personal health data with those groups than a biopharma company.9 Our 2017 report Pharma and the connected patient: How digital technology is enabling patient centricity found similar results.8 Companies need to partner with these groups to gain the trust of patients and access to meaningful data.

Access to patient data outside of the clinic will also fundamentally change how clinical trials are run. Virtual clinical trials will be run entirely outside of the clinic. Patients will be identified by screening EHRs of patients who are part of a virtual investigator network. Participants will then self-administer drugs and track outcomes through digital tools, and check in with study staff and physicians through telemedicine.

Expanding research networks
Biopharma stakeholders and regulators are pushing for more open innovation models, including master protocols – adaptive, collaborative clinical studies that allow for the simultaneous evaluation of multiple treatments for individuals with specific diseases or disease subtypes within the same trial structure. These trials require collaboration with patient advocacy groups, government agencies and researchers. According to recent research by Deloitte Insights, these protocols can provide a number of benefits, including the ability to fail fast, evaluate and compare treatment combinations or competing drugs, and risk- and cost-sharing, since the different stakeholders involved in collaborative trials share the costs related to these trials.9

Implications for partnering and operating models
Successful partnerships will require biopharma companies to shift from a procurement or acquisition mind-set to a partnership-collaboration or open innovation mind-set. In fact, Deloitte research shows that partnership models have increasingly included more open and collaborative structures and objectives over the past decade.10 Companies need to consider how to access and nurture new talent to prepare for these different models of research and partnerships, including working with stakeholders in non-traditional ways. Companies will also need to establish new teams with skills capable of identifying, establishing and cultivating partnerships with new stakeholders or collaborators.

Working in new clinical trial structures such as site-less trials or master protocols could require new operating or governance models. Companies working with collaborators on master protocols may need to reconsider what intellectual property they would own as part of the outcome of the trial, versus what would be owned by the collaborations. Also, because there are multiple stakeholders participating in these trials, companies will need to consider how to strike the right balance in research priorities and incentives for all the participating entities.

Deloitte’s view:
In order to expand access to innovation without a significant cost burden while improving cycle times, biopharma companies should look to establish and expand innovative, agile and collaborative governance structures and operating models, and adopt virtual, remote and other new kinds of clinical trials. Some of these activities will be company and therapy area specific, while others will be part of wider industry collaborations.
**Geographic clusters provide access to innovation and talent**

Some key questions many data and technology-focused organisations are struggling with are:

- where is innovation happening, and is my company positioned to benefit?
- where will future work take place and where will external digital and scientific talent be located?
- how and when will innovation move to the virtual space, in an increasingly digital world?

For biopharma companies, geography is still critical to gaining access to external talent and ideas – and companies are not looking to abandon traditional hubs in the near future. Research has shown that clustering the workforce together can encourage effective information-sharing, especially as people with diverse ideas and backgrounds share perspectives and interpret the same data in different ways (see Figure 14).

Our research has developed a system view of how to foster innovation in the biopharma space to maximise the potential for innovation – hiring people into a location alone is not enough. The key features of the system include:

- clear understanding of the market needs, fed back through to those responsible for innovation
- comprehensive body of knowledge that researchers can access to inform their thinking and simultaneously reject as therapy area dogma
- a fostered environment where learning, collaboration and intensity are created and sustained by management supporting both high performing teams as well as individuals
- a governance approach that sets clear outcomes but allows researchers full discretion on the ‘means’ to achieve the ‘ends’; this governance should also manage the instinct for additional resources – ‘necessity being the mother of invention’!
- underlying platforms giving researchers access to the widest/most relevant datasets – e.g. genomics, real-world evidence and process tools that enable faster progress.

In 2018, some biopharma companies have demonstrated commitment to expanding their innovation hubs and labs around the world to connect with technology companies better and bridge R&D development capabilities with the broader business. Some companies continue to partner with major universities, other developers of pharmaceuticals, medical devices and digital health technologies. Biopharma leaders have said that they value the two-way learning between entrepreneurs and internal staff.

Biopharma companies need to ensure they are connected to the technology companies and start-ups that are working on products and services that could improve R&D. Incentivising local talent in innovation hubs may mean companies share data and provide workspace and assistance as to how the business, and the business of R&D, functions.

**Deloitte’s view:**

In a world where company fixed infrastructure costs are under scrutiny, a vital question is whether companies are investing in the most effective forms of research infrastructure and have a presence in strategic locations to maximise opportunities for partnerships and collaborations. Once a geographic option is decided, further consideration is needed for how the innovation system will work and be measured – location alone is simply not enough to produce breakthrough innovation.
Figure 14. A new model of innovation-as-a-platform is emerging through the creation of regional clusters and collaboration between the life sciences industry, governments, academic institutions and other research groups.
Companies face leadership, funding and cultural challenges to transformation

Biopharma companies tend to be laggards instead of leaders when it comes to adopting innovation. A recent survey by Deloitte Insights and MIT Sloan Management Review (SMR) found that only 20 per cent of biopharma companies are digitally maturing. Most biopharma companies cited the lack of a clear vision, leadership and funding as key barriers to digital transformation:

- survey respondents said that they would like their leaders to create the conditions to experiment, provide a clearer vision and purpose for their organisation’s digital efforts and empower people to think differently
- 78 per cent of respondents said their organisation needs to find new leaders to succeed in the digital age. However, only 20 per cent said their companies are effectively developing the types of leaders who have the capabilities necessary to lead the organisation in a digital environment
- 54 per cent of respondents agreed that adequate funding is a major challenge to digital initiatives. In an environment where IRR continues to decline, it may be difficult to build the business case for funding digital initiatives.¹¹

Hiring from within the industry and looking for several years of experience will no longer suffice. Instead, leaders have to look for talent with analytical skill sets, who are adaptable and have the ability to learn quickly.

R&D leaders need to look beyond the private biopharma industry to seek new talent to help drive and implement the organisation’s digital efforts. External hires help bring a cultural and mind-set shift about how work is done, although the industry will need to welcome these shifts to avoid clashes that can impact productivity and lead to high employee turnover.

Several biopharma companies have made external hires at the executive level, including chief digital officers from more consumer-centric industries like retail and fashion to help drive digital transformation across the enterprise.¹² However, biopharma companies need to consider new approaches to hiring at all levels of their organisation.

Furthermore, retaining top talent will require an environment that continuously utilises the next generation of technology and provides opportunities for continuous learning and growth. Tomorrow’s talent will seek to work with companies that have adopted technology to streamline their working environment. They will also seek out companies where there is opportunity to continue to grow and develop.

Technology talent is in high demand across all industries, and biopharma companies have to compete. Competitive compensation packages, opportunities for growth and a tech-savvy work environment – combined with a compelling patient-centric mission statement – will help to attract future talent.

Deloitte’s view:

In a world of declining returns, the role of talent in productivity improvement remains paramount. In this situation, success will not be achieved without biopharma companies adopting new approaches to attracting and retaining top talent at all levels of their organisation and ensuring leadership have an understanding and a clear vision for how digital transformation can improve R&D overall and at a functional level.

Now is the time to embrace the future of work in R&D to unlock productivity

This is not a future issue: biopharma companies have to start transforming their R&D organisations now. In a recent study on biopharma levels of adoption of digital in R&D, many companies told us that when it comes to implementing new technology, they want to be fast followers.¹³ But digital transformation is a multi-year process, and companies that have not yet started will be left behind. Companies need to start to pilot new approaches to getting work done and utilising new types of talent now. This will require operating model changes to enable accelerated decision-making and faster cycles of innovation. Companies that do not start making changes now will struggle to compete with those that are already adopting new ways of working.
Appendix

Figure 15. Year-on-year drivers of change in IRR, 2010-18 – original cohort

Figure 16. Three-year rolling average returns on late-stage portfolio, 2010-18 – original and extension cohort
Figure 17. Three-year rolling average R&D cost to develop an asset from discovery to launch, 2010-18 – original and extension cohort

Figure 18. Three-year rolling average peak sales per pipeline asset, 2010-18 – original and extension cohort
Endnotes

2. Schmidt C. The struggle to do no harm in clinical trials: What lessons are being learnt from studies that went wrong? Nature, 574 vol 552. 21/28 December 2017. See also: https://www.nature.com/articles/d41586-017-08705-4
4. Deloitte analysis, 2018
12. Ibid
Authors

Mark Steedman
Manager
UK Centre for Health Solutions
Deloitte LLP
+44 (0) 20 7007 8857
msteedman@deloitte.co.uk

Karen Taylor
Director
UK Centre for Health Solutions
Deloitte LLP
+44 (0) 20 7007 3680
kartaylor@deloitte.co.uk

Julian Remnant
Partner, EMEA Life Sciences R&D Advisory Lead
Deloitte MCS Ltd
+44 (0) 20 7303 3303
jremnant@deloitte.co.uk

Hanno Ronte
Partner
Life Science & Healthcare Monitor Deloitte
+44 (0) 20 7007 2540
hronte@deloitte.co.uk

John Haughey
Partner, Life Sciences and Healthcare Leader, UK & Switzerland
Deloitte MCS Ltd
+44 (0) 20 7303 7472
jhaughey@deloitte.co.uk

Mike Standing
Partner, Life Sciences and Healthcare Leader, EMEA
Monitor Deloitte
+44 (0) 20 7007 3178
mstanding@deloitte.co.uk

Mark Stockbridge
Manager
Life Sciences R&D Advisory
Deloitte MCS Ltd
+44 (0) 20 7303 7539
mstockbridge@deloitte.co.uk

Casey Korba
Manager
US Center for Health Solutions
Deloitte Services LP
+1 (202) 748 1846
ckorba@deloitte.com

Sonal Shah
Senior Manager
US Center for Health Solutions
Deloitte Services LP
+1 (212) 653 6025
sonshah@deloitte.com

Matthew Thaxter
Research Analyst
UK Centre for Health Solutions
Deloitte LLP
+44 (0) 20 7007 7975
mthaxter@deloitte.co.uk

Neil Lesser
Principal, Life Sciences R&D Practice Leader
Deloitte Consulting LLP
+1 (215) 446 4364
nlesser@deloitte.com

Sarah Thomas
Managing Director
US Center for Health Solutions
Deloitte Consulting LLP
+1 (202) 220-2749
sarthomas@deloitte.com

Gregory Reh
Principal, Global Sector Leader Life Sciences
Deloitte Consulting LLP
+1 (215) 997 7559
grreh@deloitte.com

David Abramson
Global Director of Pharma Consulting
GlobalData
+44 (0) 20 7832 4343
david.abramson@globaldata.com

Bornadata (Bonnie) Bain, PhD
Global Head/EVP, Healthcare Operations and Strategy
GlobalData
+1 (617) 747 4136
bonnie.bain@globaldata.com

Revati Tatakta, PhD
Global Director of Databases and Analytics, Healthcare
GlobalData
+1 (646) 395 5469
revati.tatakta@globaldata.com

Mark Stockbridge
Manager
Life Sciences R&D Advisory
Deloitte MCS Ltd
+44 (0) 20 7303 7539
mstockbridge@deloitte.co.uk

Sonal Shah
Senior Manager
US Center for Health Solutions
Deloitte Services LP
+1 (212) 653 6025
sonshah@deloitte.com

Matthew Thaxter
Research Analyst
UK Centre for Health Solutions
Deloitte LLP
+44 (0) 20 7007 7975
mthaxter@deloitte.co.uk

Neil Lesser
Principal, Life Sciences R&D Practice Leader
Deloitte Consulting LLP
+1 (215) 446 4364
nlesser@deloitte.com

Sarah Thomas
Managing Director
US Center for Health Solutions
Deloitte Consulting LLP
+1 (202) 220-2749
sarthomas@deloitte.com

Gregory Reh
Principal, Global Sector Leader Life Sciences
Deloitte Consulting LLP
+1 (215) 997 7559
grreh@deloitte.com

David Abramson
Global Director of Pharma Consulting
GlobalData
+44 (0) 20 7832 4343
david.abramson@globaldata.com

Bornadata (Bonnie) Bain, PhD
Global Head/EVP, Healthcare Operations and Strategy
GlobalData
+1 (617) 747 4136
bonnie.bain@globaldata.com

Revati Tatakta, PhD
Global Director of Databases and Analytics, Healthcare
GlobalData
+1 (646) 395 5469
revati.tatakta@globaldata.com

Deloitte project team
We would like to acknowledge the significant contribution of the following people to the analysis, research and drafting of this report, without which this report would not have been possible:

GlobalData Contributors
We would like to acknowledge the contribution of Cynthia Brisac (GlobalData Pharma Consulting) and GlobalData’s Therapy Analysis and Database teams

Contact information
To see more research and sign up for future publications visit:
www.deloitte.co.uk/centreforhealthsolutions